Since then, the research effort invested into GSK3 in Alzheimer's disease has expanded, and mechanistic studies now demonstrate a functional relationship between not only GSK3 and tau, but also GSK3 and amyloid-β. Here, MAPT is linked to early-onset autosomal dominant Alzheimer disease.